Dengue Vaccine Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The dengue vaccine market encompasses approved and pipeline products designed to prevent infection by the four dengue virus serotypes (DENV-1 through DENV-4). With a 2025 valuation of approximately $0.609 billion, the segment is on track to more than double over the next decade, supported by a compound annual growth rate near 13.25%. Demand is concentrated in countries with year-round or seasonal dengue transmission, where public health authorities are increasingly integrating vaccination alongside vector-control programs.

• •Estimated 2025 market size: ~$0.609 billion (USD)
• •Forecast CAGR: ~13.25% through the early 2030s
• •Four-serotype protection is the defining technical benchmark for products in this market

Rising global dengue incidence is the principal driver, with case counts climbing in both endemic regions and previously non-endemic areas due to urbanization, climate change, and the spread of Aedes mosquito vectors. Expanded pediatric immunization programs and the rollout of newer tetravalent vaccines are accelerating adoption, while growing traveler and military demand adds incremental volume. Limited treatment options for severe dengue continue to reinforce the public-health case for preventive vaccination.

• •Dengue case numbers are rising across Latin America, South Asia, and Southeast Asia
• •Climate-related expansion of Aedes habitat is opening new endemic markets
• •Public-sector funding and WHO prequalification are supporting wider access

The market is segmented by vaccine type (live-attenuated, chimeric live-attenuated, recombinant, and others), end user (pediatric, adult, traveler), and geography, with Asia-Pacific accounting for the largest share owing to high disease burden in countries such as the Philippines, Indonesia, Thailand, India, and Sri Lanka. Latin America forms the second major regional cluster, while North America and Europe contribute primarily through traveler and outbreak-response demand. Product segmentation reflects the transition from first-generation live-attenuated vaccines to second-generation tetravalent candidates.

• •Asia-Pacific leads on volume; Latin America is the fastest-growing region in several forecasts
• •Live-attenuated tetravalent vaccines remain the dominant product class
• •Traveler and outbreak-response use is a smaller but higher-margin sub-segment

What are the recent trends and outlook?

Through the early 2030s, the market is expected to be reshaped by the global scale-up of newer tetravalent vaccines, broader pediatric indications, and potential inclusion in routine national immunization schedules. Pipeline candidates targeting seronegative populations, as well as combination products, could further expand the addressable market. Long-term outlook remains strongly positive, though growth will depend on pricing in low- and middle-income countries, regulatory approvals, and the durability of vaccine-induced immunity in real-world use.

• •Pipeline activity is focused on improved tetravalent efficacy and suitability for seronegative recipients
• •Routine pediatric adoption in endemic countries is the key upside scenario
• •Durability of protection and pricing for public tenders will determine the pace of uptake